Tyra Biosciences Company Insiders
TYRA Stock | USD 10.85 0.09 0.82% |
Tyra Biosciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Tyra Biosciences suggests that vertually all insiders are panicking. Tyra Biosciences employs about 49 people. The company is managed by 16 executives with a total tenure of roughly 115 years, averaging almost 7.0 years of service per executive, having 3.06 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-02-05 | Nina S Kjellson | Disposed 5401 @ 13.76 | View | ||
2025-01-23 | Nina S Kjellson | Disposed 4825 @ 16.26 | View | ||
2025-01-21 | Nina S Kjellson | Disposed 3993 @ 16.36 | View | ||
2025-01-16 | Nina S Kjellson | Disposed 7779 @ 16.29 | View | ||
2024-11-04 | Nina S Kjellson | Disposed 1076 @ 17.01 | View | ||
2024-11-01 | Nina S Kjellson | Disposed 27493 @ 16.56 | View | ||
2024-10-30 | Nina S Kjellson | Disposed 11078 @ 16.17 | View | ||
2024-10-21 | Todd Harris | Disposed 19084 @ 27.9 | View | ||
2024-10-17 | Todd Harris | Disposed 15394 @ 25.85 | View | ||
2024-10-15 | Todd Harris | Disposed 10035 @ 24.31 | View | ||
2024-09-30 | Todd Harris | Disposed 500 @ 24 | View | ||
2024-09-25 | Todd Harris | Disposed 600 @ 24.01 | View | ||
2024-09-23 | Todd Harris | Disposed 10092 @ 24.13 | View | ||
2024-09-19 | Todd Harris | Disposed 5698 @ 24.31 | View | ||
2024-06-10 | Daniel Bensen | Disposed 3502 @ 20 | View | ||
2024-06-07 | Daniel Bensen | Disposed 200 @ 20 | View |
Monitoring Tyra Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Tyra |
Tyra Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.2021) % which means that it has lost $0.2021 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2866) %, meaning that it created substantial loss on money invested by shareholders. Tyra Biosciences' management efficiency ratios could be used to measure how well Tyra Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.29. The current year's Return On Capital Employed is expected to grow to -0.41. At present, Tyra Biosciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.3 M, whereas Total Assets are forecasted to decline to about 179.4 M.As of March 21, 2025, Common Stock Shares Outstanding is expected to decline to about 33.8 M. The current year's Net Loss is expected to grow to about (47.3 M)
Tyra Biosciences Workforce Comparison
Tyra Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,814. Tyra Biosciences holds roughly 49.0 in number of employees claiming about 2.7% of equities under Health Care industry.
Tyra Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tyra Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tyra Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Tyra Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.125 | 1 | 8 | 37,200 | 35,267 |
2024-12-01 | 0.1379 | 4 | 29 | 5,588,638 | 3,351,580 |
2024-09-01 | 0.6667 | 6 | 9 | 882,304 | 28,554 |
2024-06-01 | 2.0 | 10 | 5 | 265,992 | 65,094 |
2024-03-01 | 0.4444 | 8 | 18 | 5,517,477 | 247,084 |
2023-09-01 | 0.8824 | 15 | 17 | 634,581 | 25,350 |
2023-06-01 | 0.5405 | 20 | 37 | 241,924 | 351,848 |
2023-03-01 | 0.6667 | 20 | 30 | 430,684 | 364,859 |
2021-09-01 | 0.46 | 23 | 50 | 36,207,753 | 14,978,045 |
Tyra Biosciences Notable Stakeholders
A Tyra Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tyra Biosciences often face trade-offs trying to please all of them. Tyra Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tyra Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Todd Harris | President, CoFounder | Profile | |
CPA CPA | Chief Officer | Profile | |
Sarah Honig | Vice Strategy | Profile | |
Erik Goluboff | Senior Development | Profile | |
Amy Conrad | Investor Contact | Profile | |
Douglas MD | Chief Officer | Profile | |
Hiroomi MD | Chief Officer | Profile | |
Lynn Scherm | F Director | Profile | |
Liz Pagano | Senior Resources | Profile | |
Robert Hudkins | Chief Officer | Profile | |
Ali JD | General Secretary | Profile | |
Daniel Bensen | CoFounder COO | Profile | |
Alan Fuhrman | Chief Officer | Profile | |
Piyush Patel | Chief Officer | Profile | |
Ronald Swanson | Chief Officer | Profile | |
Alan CPA | Chief Officer | Profile |
About Tyra Biosciences Management Performance
The success or failure of an entity such as Tyra Biosciences often depends on how effective the management is. Tyra Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tyra management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tyra management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.28) | (0.29) | |
Return On Capital Employed | (0.44) | (0.41) | |
Return On Assets | (0.28) | (0.29) | |
Return On Equity | (0.39) | (0.37) |
Please note, the presentation of Tyra Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tyra Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tyra Biosciences' management manipulating its earnings.
Tyra Biosciences Workforce Analysis
Traditionally, organizations such as Tyra Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tyra Biosciences within its industry.Tyra Biosciences Manpower Efficiency
Return on Tyra Biosciences Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.4M | |
Net Loss Per Executive | 4.3M | |
Working Capital Per Employee | 4M | |
Working Capital Per Executive | 12.3M |
Complementary Tools for Tyra Stock analysis
When running Tyra Biosciences' price analysis, check to measure Tyra Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tyra Biosciences is operating at the current time. Most of Tyra Biosciences' value examination focuses on studying past and present price action to predict the probability of Tyra Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tyra Biosciences' price. Additionally, you may evaluate how the addition of Tyra Biosciences to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Transaction History View history of all your transactions and understand their impact on performance |